Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orlowskiego CMKP
- Address
- lock Available on a paid plan
Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orlowskiego CMKP - Advanced Clinical Research Center
Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orlowskiego CMKP is a leading Polish clinical research institution conducting cutting-edge trials across multiple therapeutic areas. The center demonstrates particular expertise in neurodegenerative and neuromuscular disorders, with active programs in Parkinson's disease and Duchenne muscular dystrophy, as well as innovative research in metabolic conditions and rare diseases.
- Neurodegenerative diseases including early and moderate Parkinson's disease with novel gene therapy and monoclonal antibody approaches
- Rare genetic disorders such as Duchenne muscular dystrophy and tuberous sclerosis complex with drug-resistant epilepsy
- Metabolic and gastrointestinal conditions including short bowel syndrome and obesity management
- Infectious diseases focusing on severe viral lung infections requiring advanced respiratory support
The research center's portfolio reflects its commitment to investigating first-in-class therapies and innovative treatment modalities, including exon-skipping therapies, AAV2 gene therapy with GDNF, and novel biologics. With expertise spanning from rare pediatric conditions to complex adult metabolic disorders, the institution plays a vital role in advancing precision medicine approaches and bringing breakthrough treatments to patients with significant unmet medical needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 12 of 13 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Zealand Pharma A/S1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Zealand Pharma A/S3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orlowskiego CMKP
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials | Zealand Pharma A/S | Phase III | Not Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glepaglutide | 3 | Unknown | 2019-04-30 | 2026-01-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.